Skip to main content

How an East Bay biotech is applying its cancer know-how to a next-generation Covid vaccine

The company's stock soared more than 150% after it laid out plans Tuesday for a vaccine that could confer broader protection against the coronavirus responsible for killing more than 2 million deaths globally, including 400,000 Americans.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.